About Mazdutide (IBI362) Innovent entered into a licensing agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of OXM3 (also known as mazdutide), a GLP-1R and GCGR dual agonist, in China
Arterburn DE, Telem DA, Kushner RF, et al
GLP-1 is produced through the proteolytic processing of proglucagon, promoting insulin secretion while inhibiting glucagon production
10 This reduction in diabetes risk is crucial since T2D is associated with an increased risk of heart disease and other cardiometabolic complications
Due to its popularity, counterfeit products are being sold online as research chemicals or not for human use
Did you know that nearly half of people with type 2 diabetes rely on injectable therapies as part of their care